MRRBIZ: Global Anti-Migraine Drugs Market Trends and Opportunities (2014-19)

Global Anti-Migraine Drugs Market: Trends and Opportunities (2014-19)

The report titled “Global Anti-Migraine Drugs Market: Trends and Opportunities (2014-2019)” provides an insight into migraine drugs with a special focus on Triptans. The report also includes the market value, segmentation, types of diagnosis and treatment for migraine. It also discusses key growth drivers and upcoming trends of the market. Further, key manufacturers of anti-migraine drugs like Endo International Inc, Imapc Laboratories, GlaxoSmithKline and Pfizer Inc. are profiled in the report.

Visit Complete Report Here: 

Segments Coverage 

• Triptans
• Ergot Alkaloids
Company Coverage

• Endo International Inc.
• IMPAX Laboratories Inc.
• GlaxoSmith Kline (GSK)
• Pfizer Inc.
Executive Summary

Migraine, a condition of recurring headaches and is accompanied by symptoms like nausea, vomiting, dizziness and sensitivity to light and noise ranks among the World’s Top 20 disabling medical illnesses. It is anticipated that launches of many generic migraine drugs over the next several years will steadily increase diagnosis and drug-treatment rates, leading to sustained annual global growth of anti-migraine drugs market. Other factors contributing to the growth of these drugs include awareness among the people about proper diagnosis and treatment of migraine, rise in medical expenditures and new drugs launches.

Acute migraine treatment market is dominant by Triptans and most of them are available as pills. Triptans like Sumatriptan and Zolmitriptan are also available as nasal sprays whereas rizatriptan and zolmitriptan are available as tablets that dissolve in mouth. In next 5-10 years, cost of migraine drugs is anticipated to decline due to many generic entrants as most of them are losing their patents. Growing awareness of migraine in the emerging countries and fall in prices will facilitate the growth of anti-migraine drugs market. In addition, with the development of new treatment therapies like calcitonin gene-related peptides (CGRP) receptor antagonist and BOTOX the demand for anti-migraine drugs is anticipated to grow further.

The US is the largest market for anti-migraine drugs and there are number of companies that manufacture these drugs. Major companies include Impax, Endo Pharmaceuticals, Pfizer, GlaxoSmith Kline, Nautilus and Allergan.

Table of Content

1. Executive Summary

2. Migraine
2.1 An Overview
2.2 Different Types of Migraines
2.2.1 Migraine without Aura
2.2.2 Migraine with Aura
2.2.3 Other Types of Migraine
2.3 Diagnosis and Treatment.

Download Full Report with TOC: 

3. Anti-Migraine Drugs Market
3.1 Global Anti-Migraine Drugs Market Size (2009-2013)
3.2 Forecast- Global Anti-Migraine Drugs Market Size (2014-2019)
3.3 Segmentation by Type of Drugs Used
3.4 Migraine Specific Drugs
3.4.1 Triptan
Types of Triptans
Effectiveness of Triptans
Triptan Costs
3.4.2 Tezampanel
3.4.3 Ergots Alkaloids
3.5 Prevalence of Migraine
4. The US Migraine Market
4.1 Migraine Sufferers
4.2 Market Size
4.3 Triptans Sales

5. Migraine Market: Drivers & Challenges
5.1 Rising Healthcare Expenditures
5.2 Growth of Middle-Aged Population
5.3 Patent Expires of Migraine Drugs

6. Migraine Market: Key Challenges
6.1 Strict Regulations 
6.2 Expensive Drugs

7. Migraine Market: Upcoming Trends
7.1 Calcitonin Gene-Related Peptides (CGRP) Antibodies
7.2 BOTOX for Migraine
7.3 Anti-Migraine Headbands & Devices
7.4 New Products Development

8. Migraine Market: Competitive Landscape
9. Migraine Market: Company Profiles

Contact US:    
Office: United States
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Toll Free: 866-997-4948
Tel: +1-518-618-1030